Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of stevioside in preparation of health food and medicine for preventing or treating myocardial fibrosis

A technology of myocardial fibrosis and stevioside, which is applied in the field of stevioside, can solve the problem that stevioside has no literature reports on the prevention and treatment of myocardial fibrosis, and achieves the effect of low toxicity and good thermal stability

Active Publication Date: 2020-09-08
SUZHOU UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report on the prevention and treatment effect of stevioside on myocardial fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of stevioside in preparation of health food and medicine for preventing or treating myocardial fibrosis
  • Application of stevioside in preparation of health food and medicine for preventing or treating myocardial fibrosis
  • Application of stevioside in preparation of health food and medicine for preventing or treating myocardial fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Effect of stevioside on TGF-β1-induced expression of α-SMA, collagen I and collagen III mRNA and protein in mouse cardiac fibroblasts

[0031] The density of cultured cells was adjusted to 6×10 5 cells / ml, the cell suspension was inoculated in a 6-well culture plate, 2 ml per well, placed at 37°C, 5% CO 2 Cultured in the incubator for 24 h, and then replaced with fresh medium for the experiment.

[0032] The experiment was divided into normal control group, model group and stevioside group (concentrations were 100, 200 and 400 μM, respectively). The model group was treated with TGF-β1 10 ng / ml for 24 hours, and the stevioside group was treated with different concentrations of stevioside for 2 hours, and then treated with TGF-β1 10 ng / ml for 24 hours. Then the cells were collected and the total RNA and protein were extracted respectively. The former was used for reverse transcription and PCR amplification to measure the expression levels of α-SMA, collagen ...

Embodiment 2

[0037] Example 2: Effect of stevioside on the expression of Smad 2 / 3 mRNA and protein and P-Smad2 / 3 protein in TGF-β1-induced mouse cardiac fibroblasts

[0038] The treatment of the cells is the same as in Example 1. Figure 3 shows the effect of stevioside on the expression of Smad2 / 3 mRNA and protein and P-Smad2 / 3 protein in TGF-β1-induced cardiac fibroblasts. The results are expressed as mean ± standard deviation, n=3. Compared with normal control group, ##P<0.01; compared with model group, **P<0.01, *P<0.05.

[0039] Depend on image 3 A and image 3As shown in B, after the myocardial fibroblasts were treated with TGF-β1, the expression of Smad 2 / 3 and P-Smad 2 / 3 proteins in the cells was significantly increased compared with the control group (P image 3 The result of C showed that after being treated with different concentrations of stevioside, the expression of Smad 2 / 3 mRNA in the cells gradually decreased, and the effect of 400 μM was also obvious (P<0.01).

[0040]...

Embodiment 3

[0041] Example 3: Effect of stevioside on the expression of Smad 4 and Smad 7 mRNA and protein in TGF-β1-induced mouse cardiac fibroblasts

[0042] The treatment of the cells is the same as in Example 1. Figure 4 shows the effect of stevioside on TGF-β1-induced Smad4 and Smad7 mRNA and protein expression in cardiac fibroblasts. The results are expressed as mean ± standard deviation, n=3. Compared with normal control group, ##P<0.01, #P<0.05; compared with model group, **P<0.01, *P<0.05.

[0043] Such as Figure 4 A and Figure 4 As shown in C, the expression of Smad 4 mRNA and protein in the cells of the model group was significantly increased compared with that in the control group (P Figure 4 B and Figure 4 As shown in D, it can be seen that the expression of Smad7 mRNA and protein in the cells of the model group was significantly lower than that in the control group (P<0.05 or P<0.01), and the treatment of stevioside could increase the expression of Smad7 mRNA and prot...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of stevioside to prepare a health food and medicine for preventing or treating myocardial fibrosis. A new medicine for preventing myocardial fibrosis is provided. Since stevioside is sweet and is good in thermal stability and low in toxicity, stevioside can be used for preparing a health food.

Description

technical field [0001] The invention relates to the application of stevioside, in particular to the application of stevioside in the preparation of medicine or food for preventing and treating myocardial fibrosis. Background technique [0002] Myocardial fibrosis is a lesion phenomenon characterized by abnormal proliferation of myocardial fibroblasts, secretion of a large amount of extracellular matrix and collagen (collagen) composition imbalance, which can cause myocardial stiffness and decreased myocardial systolic function, and eventually lead to heart failure. . Myocardial fibrosis is one of the main manifestations of ventricular remodeling, and various cardiovascular diseases can cause myocardial fibrosis. In the extracellular matrix, fibrous collagen is the main structural protein, and type I and type III collagen are the main components of the myocardial collagen network, accounting for about 85% and 10% respectively. Type I collagen has tension, which determines t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P9/00A23L33/125A23F3/14A23G3/42C12G3/00A21D13/062
CPCA21D13/062A23F3/14A23G3/42A23L33/125A23V2002/00A61K31/704C12G3/00A23V2250/262A23V2200/326
Inventor 谢梅林王佳王峰薛洁
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com